SY 4798
Alternative Names: SY-4798Latest Information Update: 28 May 2024
At a glance
- Originator Shouyao Holdings
- Class Antineoplastics; Small molecules
- Mechanism of Action Type 4 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Liver cancer
- No development reported Solid tumours
Most Recent Events
- 28 May 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in China (PO, Tablet)
- 29 Aug 2022 Phase-I clinical trials in Liver cancer in China (unspecified route) (Shouyao Holdings pipeline; August 2022)
- 15 Apr 2021 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in China (PO) (NCT05498519)